EMEA/H/C/000109 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 203 | 22q11.2欠失症候群 | 1 |
203. 22q11.2欠失症候群
臨床試験数 : 5 / 薬物数 : 7 - (DrugBank : 1) / 標的遺伝子数 : 14 - 標的パスウェイ数 : 23
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2021-002011-61-NL (EUCTR) | 13/08/2021 | 21/06/2021 | Riluzole as treatment for psychotic and cognitive symptoms in 22q11.2 deletion syndrome | The glutamate/GABA balance as novel therapeutic target for psychotic and cognitive symptoms in 22q11.2 deletion syndrome - Riluzole in 22q11.2DS | 22q11.2 deletion syndrome;Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03] | Trade Name: Rilutek Product Name: Riluzole Product Code: EMEA/H/C/000109 | Academisch ziekenhuis Maastricht | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 45 | Phase 3 | Netherlands |